PUBLISHER: The Business Research Company | PRODUCT CODE: 1946992
PUBLISHER: The Business Research Company | PRODUCT CODE: 1946992
Polymerase chain reaction (PCR) devices and reagents assist researchers in generating multiple copies of specific DNA sequences. During PCR, the selected DNA segment is identified using short synthetic DNA fragments called primers, and the targeted sequence is amplified through repeated cycles of DNA synthesis.
The main products of polymerase chain reaction (PCR) devices and reagents include instruments, reagents, and consumables. Instruments are tools or systems designed to perform specific PCR-related tasks. The instrument types include standard PCR, real-time PCR (RT-PCR), and digital PCR. These products are used by end users such as pharmaceutical and biotechnology companies, clinical diagnostic laboratories and hospitals, academic institutions, and research organizations.
Tariffs have increased the cost of imported PCR instruments, enzymes, primers, and plastic consumables, raising overall operational and production expenses across the PCR market. These impacts are most significant in reagent intensive and high end instrument segments such as real time PCR and digital PCR systems, particularly in Asia-Pacific and Europe where global sourcing is common. Higher costs have affected procurement budgets for clinical laboratories and research organizations, potentially slowing equipment upgrades. However, tariffs have also encouraged local manufacturing of reagents and consumables, strengthening regional supply chains and improving long term cost stability for PCR product suppliers.
The polymerase chain reactions (pcr) devices, reagents and uses market research report is one of a series of new reports from The Business Research Company that provides polymerase chain reactions (pcr) devices, reagents and uses market statistics, including polymerase chain reactions (pcr) devices, reagents and uses industry global market size, regional shares, competitors with a polymerase chain reactions (pcr) devices, reagents and uses market share, detailed polymerase chain reactions (pcr) devices, reagents and uses market segments, market trends and opportunities, and any further data you may need to thrive in the polymerase chain reactions (pcr) devices, reagents and uses industry. This polymerase chain reactions (pcr) devices, reagents and uses market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The polymerase chain reactions (pcr) devices, reagents and uses market size has grown strongly in recent years. It will grow from $6.51 billion in 2025 to $6.97 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to infectious disease outbreaks, expansion of genomics research, growth in clinical diagnostics labs, covid-19 testing demand, adoption of molecular biology techniques.
The polymerase chain reactions (pcr) devices, reagents and uses market size is expected to see strong growth in the next few years. It will grow to $9.84 billion in 2030 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to growth in personalized medicine, rising cancer diagnostics, expansion of genetic screening, increasing research funding, demand for rapid diagnostics. Major trends in the forecast period include rising demand for molecular diagnostics, expansion of infectious disease testing, increased adoption of real-time PCR, growth of research-based pcr applications, miniaturization of pcr instruments.
The growing prevalence of infectious diseases is increasingly supporting the expansion of the polymerase chain reaction devices, reagents, and uses market going forward. Infectious diseases are caused by pathogenic microorganisms that spread through direct or indirect contact between individuals. The rate of infectious disease incidence continues to rise due to increased international travel, which facilitates rapid global transmission. Polymerase chain reaction devices, reagents, and applications enable fast and accurate pathogen detection by amplifying genetic material, supporting timely diagnosis and effective infection management. These tools also improve laboratory efficiency and outbreak response capabilities. For example, in February 2024, according to the UK Health Security Agency, tuberculosis cases in England increased to 4,850 in 2023, up 10.7% from 4,380 cases in 2022. Consequently, the increasing prevalence of infectious diseases is strengthening demand for PCR devices, reagents, and related applications.
Leading companies operating in the polymerase chain reaction (PCR) devices, reagents, and applications market are focusing on developing advanced diagnostic tools to improve the accuracy and speed of genetic testing, support early disease detection, and strengthen research capabilities across healthcare, environmental monitoring, and food safety. Advanced diagnostic tools are sophisticated technologies that enhance the precision, efficiency, and speed of disease diagnosis, enabling informed decision-making. For example, in August 2023, Gold Standard Diagnostics, a Germany-based developer of diagnostic test kits, instruments, and reagents, launched DNAllergen RT-PCR kits. These kits are molecular diagnostic tools designed for the precise detection of specific allergens in food products using real-time PCR technology. They offer enhanced sensitivity and specificity, enabling accurate identification of allergens such as almond, celery, and fish that are difficult to detect using conventional methods.
In June 2025, QIAGEN N.V., a Netherlands-based molecular diagnostics solutions provider, partnered with Gencurix Inc. Through this partnership, QIAGEN aims to develop multiplex oncology assays for tissue and liquid biopsy applications, supporting broader adoption of the QIAcuityDx digital PCR platform in clinical diagnostic laboratories. Gencurix Inc. is a South Korea-based molecular diagnostics company specializing in digital PCR assays and in vitro diagnostic solutions.
Major companies operating in the polymerase chain reactions (pcr) devices, reagents and uses market are Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Becton Dickinson and Company, Abbott Laboratories, bioMerieux S.A., Agilent Technologies Inc., QIAGEN N.V., Siemens Healthcare GmbH (Siemens AG), Fluidigm Corporation, SYGNIS Pharma AG, Takara Bio Inc., Cepheid, Lontech Laboratories, Eppendorf India Private Limited, GE Healthcare, Kapa Biosystems, Maxim Biomedical Inc., Promega Corporation, RainDance Technologies Inc., Affymetrix Inc., Beckman Coulter Inc., Enzo Life Sciences Inc., Roche Diagnostics GmbH, Merck KGaA, Danaher Corporation, Stilla Technologies, Meridian Bioscience Inc., BioFire Diagnostics LLC, Luminex Corporation, GenMark Diagnostics Inc.
North America was the largest region in the polymerase chain reactions (PCR) devices and reagents market in 2025. Western Europe was the second-largest region in the global polymerase chain reactions (PCR) devices and reagents market report. The regions covered in the polymerase chain reactions (pcr) devices, reagents and uses market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the polymerase chain reactions (pcr) devices, reagents and uses market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The polymerase chain reactions (PCR) devices and reagents market consists of sales of conventional PCR machines, qPCR, reverse transcription PCR, nested PCR, hot start PCR, and digital PCR devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Polymerase Chain Reactions (PCR) Devices, Reagents And Uses Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses polymerase chain reactions (pcr) devices, reagents and uses market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for polymerase chain reactions (pcr) devices, reagents and uses ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The polymerase chain reactions (pcr) devices, reagents and uses market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.